688670.SH
金迪克
SSE · Healthcare · Biotechnology · CN
CNY 15.01
−5.89%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 110.3M | 112.9M | 80.8M | 134.6M | 318.5M |
| Cost of Revenue | 41.7M | 40.2M | 30.2M | 29.9M | 50.6M |
| Gross Profit | 68.6M | 72.7M | 50.6M | 104.7M | 267.9M |
| Operating Expenses | |||||
| R&D Expense | 91.8M | 91.8M | 33.6M | 15.5M | 32.4M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 79.2M | 82.4M | 73.3M | 58.6M | 60.6M |
| Selling & Marketing Expense | 65.3M | 66.6M | 45.5M | 77.1M | 107.5M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 240.7M | 244.8M | 155.9M | 153.3M | 203.0M |
| Cost and Expenses | 282.4M | 285.0M | 186.1M | 183.2M | 253.6M |
| Operating Income (EBIT) | (197.1M) | (197.4M) | (114.4M) | (74.7M) | 48.9M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (197.4M) | (197.2M) | (115.8M) | (86.6M) | 48.4M |
| Income Tax Expense | (14.2M) | (18.7M) | (22.2M) | (15.6M) | 6.9M |
| Bottom Line | |||||
| Net Income | (183.3M) | (178.5M) | (93.6M) | (71.0M) | 41.5M |
| Earnings from Cont. Ops | (183.3M) | (178.5M) | (93.6M) | (71.0M) | 41.5M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (183.3M) | (178.5M) | (93.6M) | (71.0M) | 41.5M |
| Per Share | |||||
| Basic EPS | (CN¥1.48) | (CN¥1.45) | (CN¥0.76) | (CN¥0.58) | CN¥0.34 |
| Diluted EPS | (CN¥1.48) | (CN¥1.45) | (CN¥0.76) | (CN¥0.58) | CN¥0.34 |
| Revenue Per Share | CN¥0.89 | CN¥0.92 | CN¥0.66 | CN¥1.10 | CN¥2.61 |
| Shares | |||||
| Basic Shares Outstanding | 124.4M | 123.1M | 123.1M | 122.4M | 122.2M |
| Diluted Shares Outstanding | 124.4M | 123.1M | 123.1M | 122.4M | 122.2M |
| Profitability Metrics | |||||
| EBITDA | — | (166.3M) | (84.0M) | (43.4M) | 80.1M |
| D&A | — | 31.1M | 30.4M | 31.3M | 31.1M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026